// App-Quantinova.ai

6 : 177Lu-PSMA-617 (LuPSMA) versus cabazitaxel in metastatic castration-resistant prostate cancer (mCRPC) progressing after docetaxel: Updated results including progression-free survival (PFS) and patient-reported outcomes (PROs) (TheraP ANZUP 1603).

Researchers

Presenter

  • Michael S Hofman

Principal Investigators

  • Shahneen Kaur Sandhu

  • Amir Iravani

  • Anthony M. Joshua

  • Jeffrey C. Goh

  • David A. Pattison

  • Thean Hsiang Tan

  • Ian D. Kirkwood

  • Siobhan Ng

  • Roslyn J. Francis

  • Craig Gedye

  • Natalie K. Rutherford

  • Alison Yan Zhang

  • Margaret Mary McJannett

  • Martin R. Stockler

  • John A. Violet

  • Scott Williams

  • Andrew James Martin

  • Ian D. Davis

Medical Centers

  • Peter MacCallum Cancer Centre, East Melbourne, Australia

  • Department of Theranostics and Nuclear Medicine, St. Vincent's Hospital, Sydney, Australia

  • Peter MacCallum Cancer Centre, East Melbourne, Australia

  • Peter MacCallum Cancer Centre, East Melbourne, Australia

  • St Vincents Hospital, Sydney, Australia

  • Royal Brisbane and Women's Hospital, Herston and University of Queensland, Queensland, Australia

  • Royal Brisbane and Women's Hospital, Herston, Australia

  • Royal Adelaide Hospital, Adelaide, Australia

  • Sir Charles Gairdner Hospital, Perth, Australia

  • Sir Charles Gairdner Hospital, Perth, Australia

  • Calvary Mater Newcastle, Waratah, NSW, Australia

  • Calvary Mater Newcastle, Newcastle, Australia

  • NHMRC Clinical Trials Centre, The University of Sydney, Sydney, Australia

  • Australian and New Zealand Urogenital and Prostate Cancer Trials Group, Sydney, NSW, Australia

  • NHMRC Clinical Trials Centre, The University of Sydney, Sydney, Australia

  • Prostate Cancer Theranostics and Imaging Centre of Excellence, Peter MacCallum Cancer Centre, Melbourne, Australia

  • Eastern Health Clinical School, Monash University, Box Hill, VIC, Australia

Locations

  • Australia

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Urology

Disease

  • Metastatic castration-resistant prostate cancer

Biomarkers

  • Prostate specific antigen

Drug/Treatment

  • Cabazitaxel

  • Docetaxel

Outcome

  • N/A

Study Design

  • N/A

Phase

  • II

Study Id's

  • NCT03392428

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved